Gilead Sciences Inc. (NASDAQ:GILD) – European Commission Approves Gilead’s Vitekta™, an Integrase Inhibitor for the Treatment of HIV-1 Infection

November 18, 2013 at 08:00 AM EST

[Business Wire] – Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta™ tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations . . . → Read More: Gilead Sciences Inc. (NASDAQ:GILD) – European Commission Approves Gilead’s Vitekta™, an Integrase Inhibitor for the Treatment of HIV-1 Infection No similar posts.

Gilead Sciences Inc. (NASDAQ:GILD) [Business Wire] – Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta™ tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
Read more on … [visit site to read more]